Despite the conclusive benefits of SGLT2 inhibitors in patients with T2DM and HF, their efficacy and risk-benefits profile in older individuals and those with frailty remain a matter of ongoing debate and have not been systematically investigated. This evidence concerns the gene SLC5A2 and hydrops fetalis.